AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25394040
Drug: CVC 100
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC 100 mg
Trial: 25394040
Drug: CVC 200
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC 200 mg
Trial: 9305418
Drug: Nicotine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.8 mg)
Trial: 6376480
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 mg)
Trial: 9305418
Drug: Nicotine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.8 mg) + Haloperidol (5 mg)
Trial: 9305418
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Haloperidol (5 mg)
Trial: 7818614
Drug: Dosing rules
RxNorm normalized name: Rubes nigrum seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing rules for phenytoin (PHT)
Trial: 16413249
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rabeprazole
Trial: 10714565
Drug: Mutant combination
RxNorm normalized name: Streptococcus mutans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutant combination 601 + 215Y/F
Trial: 9370846
Drug: Midazolam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.03 mg.kg-1
Trial: 3514473
Drug: Ofloxacin (OFX)
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin (OFX) 2 X 200 mg/day (n = 21)
Trial: 3514473
Drug: Doxycycline (D)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline (D) 2 X 100 mg/day (n = 20)
Trial: 12860868
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose lexipafant (10 mg)
Trial: 12860868
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose lexipafant (100 mg)
Trial: 10100181
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days + chlormadinone acetate for 5 days
Trial: 10100181
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 1.25 mg/day for 21 days + chlormadinone acetate for 5 days
Trial: 17895912
Drug: Moderate vitamins
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate vitamins (vitamin C (300 mg) and E (75 IU) and folic acid (1 mg))
Trial: 17895912
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamins (vitamin C (2 g) and E (800 IU), and folic acid (5 mg))
Trial: 11136518
Drug: Subsequent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent use of larger doses of antimony
Trial: 2936772
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 gm/day for 4 weeks, then 333 mg/day for 8 weeks)
Trial: 2936772
Drug: Tetracycline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (1 gm/day for 4 weeks, then 500 mg/day for 8 weeks)
Trial: 22854666
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg hepatitis B vaccine
Trial: 18587236
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg i.v. 5‐MTHF
Trial: 8027279
Drug: Follicle Stimulating
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follicle Stimulating Hormone (FSH) 225 IU/day for 5 days
Trial: 8027279
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 ml/day for 5 days
Trial: 2524571
Drug: Chlorhexidine dihydrochloride
RxNorm normalized name: CHLORHEXIDINE DIHYDROCHLORIDE
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine dihydrochloride lozenges (5 mg, sucked three times daily after meals for 2 weeks)
Trial: 2524571
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (all ingredients except chlorhex HCl)
Trial: 29044395
Drug: Cholesterol lowering
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol lowering (mean reduction of about 1.0 mmol/L) in men with average cholesterol and no CHD
Trial: 29044395
Drug: Lowest cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest cholesterol group (mean 4.0 mmol/L)
Trial: 29044395
Drug: Highest cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest cholesterol group (mean 8.8 mmol/L)
Trial: 25816315
Drug: Inhaled UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled UMEC/VI 62.5/25 μg (delivering 55/22 μg)
Trial: 25816315
Drug: UMEC 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 62.5 μg (monotherapy)
Trial: 25816315
Drug: UMEC 125
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 125 μg (monotherapy)
Trial: 25816315
Drug: VI 25
RxNorm normalized name: VITRAKVI 25mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VI 25 μg (monotherapy)
Trial: 23609838
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri NCIMB 30242
Trial: 21840164
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) + Venlafaxine XR
Trial: 7921222
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) (5-20 micrograms every 120 min)
Trial: 31970675
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy alone (Control group)
Trial: 20488885
Drug: Rituximab 2
RxNorm normalized name: hyaluronidase-rituximab 23,400 units-1400 mg/11.7 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 2 x 1000 mg + MTX
Trial: 16166411
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment for late-life depression with Cluster C PDs
Trial: 16166411
Drug: Continuation or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation or maintenance treatment for late-life depression with Cluster C PDs
Trial: 16166411
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment for late-life depression with Cluster C PDs and residual depressive symptoms
Trial: 10548673
Drug: Forced use
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced use therapy (immobilization of the unaffected arm combined with intensive training)
Trial: 10548673
Drug: Bimanual training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual training (reference therapy based on Neuro‐Developmental Treatment)
Trial: 10548673
Drug: Forced use
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced use therapy
Trial: 7572902
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg daily)
Trial: 24292519
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg ATG
Trial: 21890719
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed antiretroviral therapy
Trial: 7745506
Drug: Synthetic surfactant
RxNorm normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic surfactant (5 ml/kg dose)
Trial: 14578781
Drug: Low-molecular-weight dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight dextran 20 cc/hour for 120 hours (n=32)
Trial: 14578781
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg/day for 120 hours (n=27)
Trial: 22136516
Drug: DHEA-S (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA-S (100 mg daily for 3 months)
Trial: 20701787
Drug: Intensive Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Insulin Treatment (IIT)
Trial: 378804
Drug: 193 mg
RxNorm normalized name: kaolin 193 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 193 mg Fe++ daily for 4 weeks
Trial: 30907187
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 2 or 4 IU daily subcutaneous injection
Trial: 30907187
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 4 IU - 6 weeks pretreatment
Trial: 30907187
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) high-quality embryo rate
Trial: 24722160
Drug: Vandetanib plus
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetanib plus gemcitabine (V/G)
Trial: 9808597
Drug: ST-segment depression,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST-segment depression, inverted T waves in >/=5 leads, TnT >/=0.1 microg/L, TnI >/=0.5 microg/L, myoglobin >/=40 microg/L, female sex, age >/=65 years
Trial: 7710149
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg sumatriptan SC
Trial: 2560514
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC (10 mg t.i.d. for 3 days and on the morning of the fourth day)
Trial: 2560514
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of THC by inhalation (18 mg/marijuana cigarette)
Trial: 6166128
Drug: Antibiotics combined
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics combined with pepsin-treated human gamma globulin (Gamma-Venin)
Trial: 11678828
Drug: Pegvisomant (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (80 mg as a single subcutaneous injection)
Trial: 3646618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine hospital feeding of up to 30 ml of sterile water at 4 HOL and up to 30 ml of formula at 8 HOL)
Trial: 20645395
Drug: Pharmacological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacological interventions (including antioxidants, anti-inflammatory drugs, vasodilators, pharmacological preconditioning, glucose infusion)
Trial: 15701468
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy (loop diuretics, ACE inhibitors/ARBs, beta-blockers, spironolactone)
Trial: 12083314
Drug: Phytostanol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytostanol treatment (3 g/d in 3 servings)
Trial: 12083314
Drug: Phytostanol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytostanol treatment
Trial: 10087722
Drug: Dexfenfluramine 30
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine 30 mg/day
Trial: 1971586
Drug: Xamoterol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (0.2 mg kg‐1 by infusion over 5 min)
Trial: 31969363
Drug: Self-reported computerised
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported computerised history taking (CHT) using a tablet.
Trial: 26500169
Drug: SMART-CPT (hybrid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART-CPT (hybrid treatment integrating CogSMART into cognitive processing therapy)
Trial: 26500169
Drug: Standard CPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CPT (Cognitive Processing Therapy)
Trial: 25059982
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg/day)
Trial: 24186866
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metformin and Sitagliptin
Trial: 19205719
Drug: Topical levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical levofloxacin four times per day in both eyes for at least 3 days
Trial: 2967310
Drug: Acitretin 75
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin 75 mg daily
Trial: 2967310
Drug: Acitretin 10
RxNorm normalized name: acitretin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin 10 mg daily
Trial: 31743233
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg/day)
Trial: 22056247
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily, with possible increases to 7 mg and 10 mg)
Trial: 6373961
Drug: B subunit
RxNorm normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit (low dose, 1.0 mg)
Trial: 28742932
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy/cognitive-behavioral therapy (MET/CBT)
Trial: 21479749
Drug: Commercial immediate-release
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial immediate-release Napilac® capsules
Trial: 23770005
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg golimumab
Trial: 17710801
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of compound Danshen injection and oral aspirin
Trial: 15100686
Drug: Aspirin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (dose not specified)
Trial: 10432262
Drug: 6-month exercise
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month exercise protocol (daily performance of five shoulder exercises: two for stretching anterior shoulder musculature and three for strengthening posterior shoulder musculature)
Trial: 7580546
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with supportive care
Trial: 7580546
Drug: Radical radiotherapy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiotherapy plus chemotherapy
Trial: 2024984
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin 0.01%
Trial: 2024984
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin 0.001%
Trial: 2024984
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin 0.05%, 0.01%, 0.001%
Trial: 6941670
Drug: Letter identification
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letter identification task (L) in HT group
Trial: 6941670
Drug: Letter identification
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letter identification task (L) in NT group
Trial: 6322961
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy plus razoxane (daily schedule: 250 mg per day)
Trial: 28771784
Drug: Standard or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard or experimental treatment
Trial: 24062200
Drug: Control patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patch with low-dose capsaicin 0.075% cream
Trial: 20416218
Drug: Compound glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound glycyrrhizin treatment
Trial: 10655967
Drug: Broccoli meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli meal (300 g/d)
Trial: 10655967
Drug: Green peas
RxNorm normalized name: green english pea allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green peas meal (300 g/d)
Trial: 10655967
Drug: Spinach meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinach meal (300 g/d)
Trial: 10655967
Drug: Beta-carotene supplemented
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplemented meal (33.3 mg)
Trial: 10655967
Drug: Broccoli and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli and green peas (per mg carotenoid consumed)
Trial: 29863280
Drug: DWP14012 (20-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 (20-160 mg once daily for 7 days)
Trial: 26822418
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) combined with physical therapy
Trial: 30917125
Drug: PRS-080#22 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRS-080#22 (doses 0.08-16 mg/kg for healthy volunteers, 2-8 mg/kg for CKD patients)
Trial: 14758145
Drug: rPAF‐AH 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPAF‐AH 1.0 mg/kg intravenously once daily for five consecutive days
Trial: 9253907
Drug: Oxandrolone +
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone + high-protein diet (2 g/kg/day)
Trial: 9253907
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet alone (2 g/kg/day)
Trial: 9253907
Drug: Retrospective group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective group (high-calorie, high-protein diet with 1.3 to 1.4 g/kg/day)
Trial: 29862410
Drug: Tart cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart cherry juice (480 ml daily for 12 weeks)
Trial: 21882288
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment for depression (psychotherapy plus antidepressants)
Trial: 21882288
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (antidepressants alone)
Trial: 11579009
Drug: Drug-free comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free comparison group
Trial: 31326319
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg twice a day for 12 weeks
Trial: 19090788
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering therapy with atorvastatin
Trial: 19090788
Drug: Moderate lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate lipid-lowering therapy with pravastatin
Trial: 11033746
Drug: Preparation for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation for Parenthood groups (psychosocial intervention)
Trial: 8170484
Drug: Deflazacort 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort 2.0 mg/kg alternate-day therapy
Trial: 3046332
Drug: Cyclosporine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (5 mg/kg/d)
Trial: 20554506
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment initially)
Trial: 12898459
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) treatment
Trial: 18004131
Drug: Flunitrazepam (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1.25 mg)
Trial: 16647412
Drug: Plant stanols
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanols (2.0 g daily in low-fat yogurt)
Trial: 10793592
Drug: MIKE (ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIKE (ketamine 3 mg kg‐1, midazolam 0.5 mg kg‐1)